The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction

Kojima, Sunao; Funahashi, Tohru; Sakamoto, Tomohiro; Miyamoto, Shinzo; Soejima, Hirofumi; Hokamaki, Jun; Kajiwara, Ichiro; Sugiyama, Seigo; Yoshimura, Michihiro; Fujimoto, Kazuyuki; Miyao, Yuji; Suefuji, Hisakazu; Kitagawa, Akira; Ouchi, Noriyuki; Kihara, Shinji; Matsuzawa, Yūji; Ogawa, Hisao

doi:10.1136/heart.89.6.667

Cited by 180 publications

(120 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous epidemiological studies have revealed the correlation of reduced Ad levels with increased cardiovascular disease risk (18,23,30,74), and the relationship persists even after adjustment for diabetes, dyslipidemia, hypertension, smoking, and BMI (28,30). High plasma Ad concentrations are associated with a lower risk of MI in men (17,30,49).…”

Section: Ad and Cardiac Injurymentioning

confidence: 99%

Systemic Adiponectin Malfunction as a Risk Factor for Cardiovascular Disease

Tao¹,

Wang²,

Li³

et al. 2011

Antioxidants & Redox Signaling

View full text Add to dashboard Cite

Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes. The 30 kDa protein originates from adipose tissue, with full-length and globular domain circulatory forms. A collagenous domain within Ad leads to spontaneous self-assemblage into various oligomeric isoforms, including trimers, hexamers, and high-molecular-weight multimers. Two membrane-spanning receptors for Ad have been identified, with differing concentration distribution in various body tissues. The major intracellular pathway activated by Ad includes phosphorylation of AMP-activated protein kinase, which is responsible for many of Ad's metabolic regulatory, anti-inflammatory, vascular protective, and anti-ischemic properties. Additionally, several AMP-activated protein kinase-independent mechanisms responsible for Ad's anti-inflammatory and antiischemic (resulting in cardioprotective) effects have also been discovered. Since its 1995 discovery, Ad has garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and insulin resistance. In this review, we elaborate currently known information about Ad malfunction and deficiency pertaining to cardiovascular disease risk (including atherosclerosis, endothelial dysfunction, and cardiac injury), as well as review evidence supporting Ad resistance as a novel risk factor for cardiovascular injury, providing insight about the future of Ad research and the protein's potential therapeutic benefits.

show abstract

Section: Ad and Cardiac Injurymentioning

confidence: 99%

Systemic Adiponectin Malfunction as a Risk Factor for Cardiovascular Disease

Tao¹,

Wang²,

Li³

et al. 2011

Antioxidants & Redox Signaling

View full text Add to dashboard Cite

show abstract

“…9,10 An increasing body of evidence has shown low-adiponectin levels to predict risk of developing diabetes. [11][12][13][14][15][16] Although an inverse association has been found between adiponectin and prevalent coronary heart disease (CHD) in crosssectional studies, 17,18 prospective studies have produced conflicting results. [19][20][21][22] It remains uncertain whether adiponectin is a critical factor in the 'common soil' 23 leading to both diabetes and cardiovascular disease.…”

Section: Introductionmentioning

confidence: 99%

Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters

et al. 2007

View full text Add to dashboard Cite

Background and aim: Adiponectin is considered by many to be part of the 'common soil' linking type 2 diabetes and coronary heart disease (CHD). We examined the relationship between adiponectin and insulin resistance, metabolic, inflammatory and haemostatic risk factors and hepatic function. Methods and results: The study was carried out in 3640 non-diabetic men aged 60-79 years drawn from general practices in 24 British towns and who were not on warfarin. Adiponectin was associated with waist circumference (inversely), alcohol intake (positively) and physical activity (nonlinearly); no association was seen with cigarette smoking, prevalent CHD or stroke. After adjustment for these factors, adiponectin was significantly inversely associated with insulin resistance, triglyceride, C-reactive protein (but not interleukin 6), tissue plasminogen activator and alanine aminotransferase and positively associated with highdensity lipoprotein cholesterol (HDL-cholesterol) and Factor VIII, factors associated with diabetes. No association was seen with cholesterol, smoking, systolic blood pressure or coagulation factors. Risk of the metabolic syndrome decreased significantly with increasing adiponectin. Conclusion: Adiponectin is inversely associated with factors strongly associated with the development of diabetes. Limited associations with the established major risk factors for CHD suggest adiponectin may be a stronger marker of risk for diabetes than for CHD.

show abstract

“…Plasma adiponectin levels were recently shown to be declined after myocardial ischemia-reperfusion injury (Kojima et al 2003). Ischemia-reperfusion injury syndrome commonly occurs after achievement of adequate coronary recirculation (Bulkley and Hutchins 1977;Ferreira et al 1990).…”

Section: Discussionmentioning

confidence: 99%

Coronary Artery Bypass Grafting Ameliorates the Decreased Plasma Adiponectin Level in Atherosclerotic Patients

Eyileten

Yılmaz

Kaya³

et al. 2007

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Adiponectin functions as an anti-inflammatory and antiatherogenic factor, and the decreased plasma adiponectin is a risk factor for coronary disease. The aim of this study was to determine the changes in plasma levels of adiponectin, a potential parameter for atherosclerosis, in patients underwent surgical revascularization. We included forty patients with atherosclerosis (age, 58 ± 9 years; body mass index [BMI] 26.93 ± 2.3 kg/m 2 ) undergoing coronary artery bypass grafting (CABG). Control group consisted of 40 healthy volunteers, matched for age, gender and BMI (age, 56 ± 6 years; BMI, 26.78 ± 2.3 kg/m 2 ). We measured various parameters, including high sensitive Creactive protein (hsCRP), homeostasis model assessment-insulin resistance (HOMA-IR) indexes, and adiponectin. The baseline profile of the patients before CABG showed higher levels of serum hsCRP (13.15 ± 2.40 mg/l vs 3.97 ± 1.07 mg/l) and HOMA-IR (1.86 ± 0.30 vs 1.26 ± 0.33) and lower plasma adiponectin levels (7.02 ± 2.01 μ g/ml vs 25.46 ± 3.9 μ g/ml), compared to controls ( p < 0.001 for each parameter). Plasma adiponectin level was increased one month after CABG from the baseline level to 8.67 ± 2.05 μ g/ml ( p < 0.001), although the level was still lower than the control value. Thus, postoperative adiponectin level might be helpful for evaluating the progression of atherosclerosis. Moreover, CABG significantly decreased hsCRP to 7.25 ± 1.89 mg/l and HOMA-IR to 1.59 ± 0.33, although these levels were higher than the controls. These results suggest that CABG decreases the cardiac risk factors in atherosclerotic patients.adiponectin; coronary artery bypass grafting; insulin sensitivity; oxidative stress

show abstract

The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction

Cited by 180 publications

References 5 publications

Systemic Adiponectin Malfunction as a Risk Factor for Cardiovascular Disease

Systemic Adiponectin Malfunction as a Risk Factor for Cardiovascular Disease

Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters

Coronary Artery Bypass Grafting Ameliorates the Decreased Plasma Adiponectin Level in Atherosclerotic Patients

Contact Info

Product

Resources

About